Rankings / Sleep & Recovery

DORAs (suvorexant / lemborexant / daridorexant)

Sleep & Recovery · Orexin receptor antagonists

Tier A-

Reviewed by Read Off Label · Last reviewed · How we grade

orexincontrolled-substanceprescription
7.6 / 10
Tier A-
Ev 8 Bn 8 Sf 7

Bottom line

Read Off Label grades DORAs (suvorexant / lemborexant / daridorexant) as A- (7.6/10) based on strong evidence, strong benefit magnitude, and a low-med-risk safety profile.

This newer hypnotic class has multiple Phase 3 trials and daytime-function data.

Studied, labeled, or reported-use context: Suvorexant 10-20 mg; lemborexant 5-10 mg; daridorexant 25-50 mg PO at bedtime — Rx; not individualized guidance.

What the evidence says

This newer hypnotic class has multiple Phase 3 trials and daytime-function data. Daridorexant (Quviviq, approved 2022) has the best daytime functioning data. Expensive at brand prices. Mechanism preserves natural sleep architecture better than sedating hypnotics. Concurrent heavy alcohol use increases CNS-depressant risk. A 2026 systematic review/meta-analysis (~5,000 patients) found DORAs comparable to or better than benzodiazepine-receptor agonists for chronic insomnia — daridorexant 50 mg non-inferior to zolpidem 10 mg, with sleep latency shortened ~15 min more than BZRAs.

Mechanism

Dual orexin receptor antagonists block OX1R/OX2R-mediated wakefulness signaling; work by reducing wake drive rather than increasing sedation (unlike benzo/Z-drugs); preserve sleep architecture better

Studied, labeled, or reported dose & route

Suvorexant 10-20 mg; lemborexant 5-10 mg; daridorexant 25-50 mg PO at bedtime

This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.

Citations

A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.

Common questions

What does the evidence show about DORAs (suvorexant / lemborexant / daridorexant)'s effects?
Read Off Label rates the evidence for DORAs (suvorexant / lemborexant / daridorexant) as Strong and the benefit magnitude as strong, producing an overall grade of A- (7.6/10). This newer hypnotic class has multiple Phase 3 trials and daytime-function data.
What safety findings are reported for DORAs (suvorexant / lemborexant / daridorexant)?
DORAs (suvorexant / lemborexant / daridorexant) has a low-med risk profile in the database. Low-Med (daytime sleepiness at high doses; rare sleep paralysis, hypnagogic hallucinations, cataplexy-like events; no abuse/dependence signal comparable to Z-drugs; expensive) Legal status: Rx (Schedule IV US).
What doses or routes are reported for DORAs (suvorexant / lemborexant / daridorexant)?
Suvorexant 10-20 mg; lemborexant 5-10 mg; daridorexant 25-50 mg PO at bedtime This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
How does DORAs (suvorexant / lemborexant / daridorexant) work?
Dual orexin receptor antagonists block OX1R/OX2R-mediated wakefulness signaling; work by reducing wake drive rather than increasing sedation (unlike benzo/Z-drugs); preserve sleep architecture better

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.